Abstract -A predictive design is explored with nitroxyl labeled derivatives, and other congeners of alkylating drugs TEPA/Thio-TEPA, CCNU/MeCCNU, and Streptozotocin/Chlorozotocin. The design is based on correlations of lipophilicities of these drugs with their antineoplastic activities i n vivo against the murine lymphocytic leukemia P388. Some results are also included of evaluations using the nturine lymphoid leukemia L1210. therapeutic indices than those of the parent drugs which are in clinical use, and, hence, warrant further studies.
INTRODUCTION
Cancer diseases existed during the whole evolutionary process of multicellular organisms (ref. 1,2). This fact is not surprising, considering that all cancers, in spite of their diversities, have also common, unifying features, i.e., they involve intracellular events, more specifically, they involve the malfunctioning of the genetic mechanism which guaranties the hereditary pattern of proliferation and survival of individual species, the DNA (ref. 3). Hence, the development of new antineoplastic drugs should be aimed at a selective destruction of the DNA coding of the cancerous cells without affecting the DNA of the healthy cells. This task can only be achieved by a design of drugs which would contain components capable of a decisive interaction with the DNA coding mechanism, and, furthermore, would ensure a selective permeation of the drug through the cancerous cell membranes, and not the healthy cell membranes. aspect has been extensively investigated, the latter aspect has not been widely considered in various designs of antineoplastic drugs.
It is surprising that while the former

CORRELATION OF ANTINEOPLASTIC ACTIVITY WITH LlPOPHlLlClTY
The transformation of a healthy cell into a malignant cell is accompanied by at least a few dozen of known, and, probably, by an additional number of unknown changes (ref. 3,4,5). Therefore, it would be a futile undertaking to attempt to design an antitumor drug taking into account all the possible known and assumed parameters. therapy the cancer cell is continually undergoing further recognizable and unrecognizable transformations. As a consequence, considering our present still highly inadequate scientific capabilities, it would be a more manageable task to select, if posssible, a dominant parameter which would permit an approximate correlation between the structure and anticancer activity. Over the years it has been well recognized (refs. 6,7,8,9 ) that the most important property of many biologically active compounds is their lipophilicity which can be conveniently measured by the partition coefficient using, e.g., the octanol/water solvent system. The reason for the dominant role of the partition coefficient in correlating the structure with the activity of a drug can be plausibly explained. Thus, since it can be considered as established (ref. 1,2,3) that all cancer diseases are diseases affecting the DNA, in combating any cancer disease it is essential to design a drug which would selectively reach the cancerous DNA, but not the DNA of the healthy cell. In order for a drug to reach the DNA, it will have to be compatible with aqueous extracellular and cell surface environment, independent of the mode of permeation through the cell membranes. In addition, in order to permeate through the highly hydrophobic bilayer of the membrane, the drug must also possess a certain degree of compatibility with this hydrophobic environment. We hypothesized that a more effective drug(s) could be designed by either aAnticancer activity against P388 lymphocytic leukemia in CD2Fl male mice. National Cancer Institute protocol followed exactly.
these compounds and of several additional congeners 1-u are shown in Table 1 , and the correlations are graphically presented in Fig. 1 . It will be noticed, that while for a linear correlation at the hydrophobic side a sufficient number of points could be obtained, at the hydrophilic side, to date, only two values are available. ConsequentIy, only for the hydrophobic side a mathematical expression is rendered. According to this presentation the most effective compound in this series is the nitroxyl labeled analog 3 of CCNU.
TEPA A N D THIO-TEPA DERIVATIVES
A more complete series of correlations of activities with lipophilicities ( Fig. 1) was obtained with congeners u -; L 2 of TEPA (u) and Thio-TEPA (u) shown in Tables 2 and 3 . Thio-TEPA (u) has been used clinically in the chemotherapy of Hodgkin disease, metastatic carcinoma of the breast, superficial papillary carcinoma of the bladder, carcinomatous meningitis, and ovarian cancer (refs. 3,11,19) . TEPA (u) which is probably the first metabolite of u (refs. 19,20) was not introduced into oncology, although the therapeutic indicies (refs. 21,22) and OILS parameters (Table 2) are very similar for both compounds (refs. 21,22) . In contrast, their lipophilicity characteristics are entirely different (ref. 22) . Thus, while JJ is fairly hydrophilic (log P --0.62), compound u is relatively hydrophobic (log P -+0.41) as shown in Table 2 . As mentioned earlier, the more effective drug(s) would be expected to possess a partition coefficient somewhere between those of ;Ls and JJ.
synthesized (refs. 22,23,24) and their activity and lipophilicity parameters determined (Tables 2 and 3 ) . evaluations have been adequately reported elsewhere (refs. 22,23,24) . were found (refs. 22) to be less active than the corresponding nitroxyl derivatives ( (Table 3) . contribute to a decrease in toxicity of alkylating anticancer drugs, and facilitate a selective permeation of such drugs through cell membranes (refs. 22,23,26) . A more detailed rationale in support of this contention was previously delineated (refs. 22,23) .
Recapitulating, the effectiveness of an alkylating anticancer drug depends on its alkylating potential, and its capability to permeate selectively through cell membranes. The latter property is linked to the lipophilicity of the drug. Synthetic manipulations based on lipophilicity and anticancer activity correlations can lead to a predictive design of new anticancer drugs. Replacement of certain components in the clinical alkylating drugs of nitrosourea and TEPA/Thio-TEPA type with nitroxyl, nitroxyl labeled urea, polyether and carbohydrate moieties can substantially alter the lipophilicity of the parent drugs with concomitant lowering of toxicity and often, but not always, increase in activity which will depend on the degree of attained lipophilicity. Other components in the molecule, such as, alkyl, cycloalkyl and sulfur groups increase the hydrophobicity of the drugs (Tables 1-3) . Thus, the carbohydrate moiety in Streptozotocin/Chlorozotocin imparts a fairly hydrophilic character to these drugs. A replacement of the carbohydrate moiety with cyclohexyl moieties results in the rather hydrophobic drugs CCNU/MeCCNU without significant change in activities (Table 1) . The nitroxyl moiety can be used to provide a finer shift of lipophilicity, either to the hydrophilic or hydrophobic region, depending on the lipophilicity of the parent compound. Thus, the nitroxyl labeled analogs 3 and SLGNU (6) of Streptozotocin/ Chlorozotocin are more hydrophobic and more active than the parent compounds, but not as hydrophobic as CCNU/MECCNU (Table 1 , Fig. 1 ). In contrast, the replacement of the cyclohexyl groups in CCNU/MeCCNU by a nitroxyl moiety results in more hydrophilic drugs SLCNU ( 3 ) and 4 with higher activity than the parent drugs, 9 and u. Acylation (Ref. 28) of 3 and 6 results in more hydrophobic and less active derivatives z and &, respectively (Table 1 , Fig. 1 ). The replacement of one aziridine group in TEPA (u) with either a nitroxyl labeled urea or a suitable azacrown moiety results in an increased hydrophobicity and activity of analog SLDU (u) and azacrown TEPA (x), respectively.
It is believed that the nitroxyl radical moieties and polyether moieties
All these results, obtained with P388 leukemia, can not be automatically used to predict the effectiveness of these drugs in other than leukemia tumors (ref. 
